The role of meldonium and individualized physical activities in the treatment of patients with heart failure

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509804-14-00

Acronym

MELD-PHYS-2023

Enrollment

200

Registered

2024-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure with preserved ejection fraction

Brief summary

Physical activity tolerance change asessed by the cardiopulmonary test (relative maximal oxygen uptake, VO2 max ml/min/kg)

Interventions

DRUGMELDONIUM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Physical activity tolerance change asessed by the cardiopulmonary test (relative maximal oxygen uptake, VO2 max ml/min/kg)	—

Countries

Latvia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026